BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1817 related articles for article (PubMed ID: 31100225)

  • 21. Multiparametric magnetic resonance imaging and follow-up to avoid prostate biopsy in 4259 men.
    Venderink W; van Luijtelaar A; van der Leest M; Barentsz JO; Jenniskens SFM; Sedelaar MJP; Hulsbergen-van de Kaa C; Overduin CG; Fütterer JJ
    BJU Int; 2019 Nov; 124(5):775-784. PubMed ID: 31237388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer.
    Pepe P; Garufi A; Priolo G; Pennisi M
    Clin Genitourin Cancer; 2017 Feb; 15(1):e33-e36. PubMed ID: 27530436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnostic efficacy of prostate cancer using targeted biopsy with 6-core systematic biopsy for patients with PI-RADS 5].
    Liu Y; Yuan CW; Wu JY; Shen Q; Xiao JX; Zhao Z; Wang XY; Li XS; He ZS; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):812-817. PubMed ID: 37807733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiparametric MRI in men with clinical suspicion of prostate cancer undergoing repeat biopsy: a prospective comparison with clinical findings and histopathology.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Thomsen HS
    Acta Radiol; 2018 Mar; 59(3):371-380. PubMed ID: 28679325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
    Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
    Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
    Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
    Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Prospective Comparison of Selective Multiparametric Magnetic Resonance Imaging Fusion-Targeted and Systematic Transrectal Ultrasound-Guided Biopsies for Detecting Prostate Cancer in Men Undergoing Repeated Biopsies.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Thomsen HS
    Urol Int; 2017; 99(4):384-391. PubMed ID: 28651247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.
    Pellegrino F; Stabile A; Sorce G; Quarta L; Robesti D; Cannoletta D; Cirulli G; Barletta F; Scuderi S; Mazzone E; de Angelis M; Brembilla G; De Cobelli F; Salonia A; Montorsi F; Briganti A; Gandaglia G
    Eur Urol Focus; 2023 Oct; ():. PubMed ID: 37865591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
    Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series.
    Stabile A; Barletta F; Motterle G; Pellegrino F; Sorce G; Mazzone E; Scuderi S; Cirulli GO; Cucchiara V; Esposito A; Gandaglia G; Fossati N; De Cobelli F; Montorsi F; Karnes RJ; Briganti A
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1137-1142. PubMed ID: 33941867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer.
    Stabile A; Dell'Oglio P; Soligo M; De Cobelli F; Gandaglia G; Fossati N; Esposito A; Brembilla G; Karnes RJ; Montorsi F; Briganti A
    Eur Urol Oncol; 2021 Aug; 4(4):594-600. PubMed ID: 31204312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
    Mazzone E; Stabile A; Pellegrino F; Basile G; Cignoli D; Cirulli GO; Sorce G; Barletta F; Scuderi S; Bravi CA; Cucchiara V; Fossati N; Gandaglia G; Montorsi F; Briganti A
    Eur Urol Oncol; 2021 Oct; 4(5):697-713. PubMed ID: 33358543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer.
    Panebianco V; Valerio MC; Giuliani A; Pecoraro M; Ceravolo I; Barchetti G; Catalano C; Padhani AR
    Eur Urol Oncol; 2018 Aug; 1(3):208-214. PubMed ID: 31102623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
    Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
    J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database.
    Barletta F; Mazzone E; Stabile A; Scuderi S; Brembilla G; de Angelis M; Cirulli GO; Cucchiara V; Gandaglia G; Karnes RJ; Roupret M; De Cobelli F; Montorsi F; Briganti A
    World J Urol; 2022 Nov; 40(11):2683-2688. PubMed ID: 36149448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Central zone lesions on magnetic resonance imaging: Should we be concerned?
    Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
    Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 91.